| Literature DB >> 26037925 |
Nora Pällmann1, Melanie Braig2, Henning Sievert3, Michael Preukschas4, Irm Hermans-Borgmeyer5, Michaela Schweizer5, Claus Henning Nagel6, Melanie Neumann7, Peter Wild8, Eugenia Haralambieva8, Christian Hagel7, Carsten Bokemeyer3, Joachim Hauber6, Stefan Balabanov9.
Abstract
Hypusine modification of the eukaryotic initiation factor 5A (eIF-5A) is emerging as a crucial regulator in cancer, infections, and inflammation. Although its contribution in translational regulation of proline repeat-rich proteins has been sufficiently demonstrated, its biological role in higher eukaryotes remains poorly understood. To establish the hypusine modification system as a novel platform for therapeutic strategies, we aimed to investigate its functional relevance in mammals by generating and using a range of new knock-out mouse models for the hypusine-modifying enzymes deoxyhypusine synthase and deoxyhypusine hydroxylase as well as for the cancer-related isoform eIF-5A2. We discovered that homozygous depletion of deoxyhypusine synthase and/or deoxyhypusine hydroxylase causes lethality in adult mice with different penetrance compared with haploinsufficiency. Network-based bioinformatic analysis of proline repeat-rich proteins, which are putative eIF-5A targets, revealed that these proteins are organized in highly connected protein-protein interaction networks. Hypusine-dependent translational control of essential proteins (hubs) and protein complexes inside these networks might explain the lethal phenotype observed after deletion of hypusine-modifying enzymes. Remarkably, our results also demonstrate that the cancer-associated isoform eIF-5A2 is dispensable for normal development and viability. Together, our results provide the first genetic evidence that the hypusine modification in eIF-5A is crucial for homeostasis in mammals. Moreover, these findings highlight functional diversity of the hypusine system compared with lower eukaryotes and indicate eIF-5A2 as a valuable and safe target for therapeutic intervention in cancer.Entities:
Keywords: cancer therapy; eukaryotic initiation factor 5A (eIF5A); mouse genetics; post-translational modification (PTM); translation elongation factor
Mesh:
Substances:
Year: 2015 PMID: 26037925 PMCID: PMC4513096 DOI: 10.1074/jbc.M115.664490
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157